Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
580 people get OCLS articles and Market Currents by email alert.
Get email alerts on OCLS »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
Oculus Launches Wound Treatment Product in ChinaChinaBio Today • Sun, Sep 14, 2008 -
-
Oculus Receives SFDA Approval for Wound TreatmentChinaBio Today • Tue, Apr 1, 2008
-
Oculus Innovative Sciences IPO Analysis: Six Month ReviewPharmaTracker • Mon, Aug 13, 2007
-
IPO Watch: Oculus Seeks Foothold In Wound HealingCentient Biotech Investor • Thu, Jan 25, 2007 -
New Terms for Oculus Innovative Sciences IPOSA Editor Abbi Adest • Sun, Jan 14, 2007
-
-
-
China Biotech In Review: Deals, Trials And RegulationsChinaBio Today • Sun, Jul 15, 2012
-
-
-
A Look at 5 Stocks in the Green WednesdayAlex Shadunsky • Thu, Jul 28, 2011 -
-
China Biotech Week in Review: CROs ConsolidatingChinaBio Today • Sun, Nov 22, 2009
-
Oculus Wins China Approval for Animal Wound ProductChinaBio Today • Tue, Nov 17, 2009
-
-
-
-
-
China Biopharma Week in Review: Broad Views, Individual CompaniesChinaBio Today • Sun, Sep 14, 2008
-
China Biotech in Review: A Week of CollaborationsChinaBio Today • Sun, Jun 29, 2008
-
Oculus to Use Bayer for Approval of Wound Treatment in AnimalsChinaBio Today • Wed, Jun 25, 2008
-
Following the China Biopharma BeatChinaBio Today • Sun, May 25, 2008
-
Downturn in China Biotech Stocks Shows No Impact on ActivityChinaBio Today • Mon, Apr 7, 2008
-
-
-
GlobeNewswire (Thu, 4:05PM)
-
GlobeNewswire (Jun 6, 2013)
-
GlobeNewswire (May 23, 2013)
-
GlobeNewswire (Apr 10, 2013)
-
GlobeNewswire (Mar 28, 2013)
-
GlobeNewswire (Mar 26, 2013)
-
GlobeNewswire (Mar 20, 2013)
-
GlobeNewswire (Mar 14, 2013)
-
GlobeNewswire (Mar 12, 2013)
-
GlobeNewswire (Mar 7, 2013)
-
at MarketWatch.com (Mar 7, 2013)
-
GlobeNewswire (Feb 13, 2013)
OCLS vs. ETF Alternatives
Company Description
Currently, there's no company description for OCLS.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, June 13, 6:59 PM More on Oculus (OCLS): FQ4 misses across the board. Product revenues, including licensing fees, were flat Y/Y, with increases in Europe, China, India and Singapore offset by declines in the United States and Mexico. The company cites its More Pharma transaction, which reduced short-term revenue growth despite a 49% increase in unit volume sales, and the delayed seasonal purchasing in the ranch and farm animal market of its Vetericyn animal healthcare products due to late winter storms. Shares -1.4% AH. Comment! [Healthcare, Earnings, On the Move]
- Thursday, June 13, 4:15 PM Oculus (OCLS): Q1 EPS of -$0.44 misses by $0.31. Revenue of $3.34M misses by $0.53M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Wednesday, February 13, 6:40 PM Oculus Innovative Sciences (OCLS): FQ3 EPS of -$0.05 beats by $0.03. Revenue of $3.5M (+27% Y/Y) beats by $0.22M. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
hitekmastr
$OCLS recently received an unsubstantiated hit by an online pundit who posted some misleading information, which dropped the stock. - View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-